A randomized controlled trial for the effect of Modified Shenling Baizhu Powder on delaying the illness progress of COPD stable phase patients (GOLD 1-2 stages).

Department of Respiratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. Patients with a clinical diagnosis of stable COPD (GOLD stage 1-2); consistent with TCM lung qi deficiency syndrome;
•2. No history of respiratory tract infection or acute exacerbation in the 4 weeks prior to randomization;
•3. Those who are able to successfully perform pulmonary function measurements;
•4. Patients are informed and sign written consent form.

•1. Patients with chronic lung diseases in which intervention or treatment is required, such as interstitial lung diseasebronchial asthma, active tuberculosis, or bronchiectasis;
•2. Patients with a combination of severe primary diseases, such as cardiovascular and cerebrovascular diseases, liver and kidney diseases, hematopoietic system diseases, endocrine diseases, severe mental disorders, malignant tumors;
•3. Patients have evidence of alcohol or drug abuse, known or suspected allergy to the study drug or some of its components, and currently uses oral corticosteroids regularly;
•4. Women who are breast-feeding, pregnant or expecting a child;
•5. Patients who have been involved in any other clinical study in the past 6 months;
•6. Patients unable to successfully use a DPI or perform pulmonary function measurements.

发起方

Department of Respiratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine